Agios (NASDAQ: AGIO) director receives new stock options and RSU awards
Rhea-AI Filing Summary
AGIOS PHARMACEUTICALS director Jeffrey D. Capello reported equity awards and vesting activity. On June 18, 2026, 2,816 restricted stock units converted into the same number of common shares, increasing his direct holdings to 10,865 shares.
He also received new grants of 14,950 stock options with an exercise price of $34.16 per share, expiring on June 18, 2036, and 2,927 restricted stock units. According to the footnotes, options and RSUs granted on June 18, 2026 vest in full on June 18, 2027, with vested shares delivered within three business days. Earlier RSUs granted June 18, 2025 vest in full on June 18, 2026. These are compensation-related grants and exercises, not open-market purchases or sales.
Positive
- None.
Negative
- None.
Insider Trade Summary
Net Buyer: 2,816 shares
Net Buy
4 txns
Insider
CAPELLO JEFFREY D
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Restricted stock units | 2,816 | $0.00 | $0.00 |
| Grant/Award | Restricted stock units | 2,927 | $0.00 | $0.00 |
| Grant/Award | Stock options (right to buy) | 14,950 | $0.00 | $0.00 |
| Exercise | Common stock | 2,816 | $0.00 | $0.00 |
Holdings After Transaction:
Restricted stock units — 2,927 shares (Direct);
Stock options (right to buy) — 14,950 shares (Direct);
Common stock — 10,865 shares (Direct)
Footnotes (4)
- F1. Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock.
- F2. The restricted stock units were granted on June 18, 2025. The shares underlying the stock units will vest in full on June 18, 2026. Vested shares will be delivered to the reporting person within three business days after such shares become vested.
- F3. The restricted stock units were granted on June 18, 2026. The shares underlying the stock units will vest in full on June 18, 2027. Vested shares will be delivered to the reporting person within three business days after such shares become vested.
- F4. These options were granted on June 18, 2026. The shares underlying these options vest as to 100% of the underlying shares on June 18, 2027.
Key Figures
Common shares after transaction: 10,865 shares
RSUs converted to common: 2,816 shares
New stock options granted: 14,950 options
+5 more
8 metrics
Common shares after transaction
10,865 shares
Direct holdings following June 18, 2026 RSU conversion
RSUs converted to common
2,816 shares
Restricted stock units exercised into common stock on June 18, 2026
New stock options granted
14,950 options
Grant on June 18, 2026, right to buy common stock
Option exercise price
$34.16 per share
Exercise price for 14,950 stock options granted June 18, 2026
Option expiration date
June 18, 2036
Expiration for 14,950 stock options
New RSUs granted
2,927 units
Restricted stock units granted June 18, 2026
Vesting date 2026 RSUs and options
June 18, 2027
Full vesting date for 2026 RSUs and options grants
Vesting date 2025 RSUs
June 18, 2026
Full vesting date for RSUs granted June 18, 2025
Key Terms
Restricted stock units, Stock options (right to buy), Exercise or conversion of derivative security, Grant, award, or other acquisition, +1 more
5 terms
Restricted stock units financial
"Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock."
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
Stock options (right to buy) financial
"Stock options (right to buy) with an exercise price of 34.1600 per share were granted."
Exercise or conversion of derivative security financial
"Transaction code M is described as Exercise or conversion of derivative security."
Grant, award, or other acquisition financial
"Transaction code A is described as Grant, award, or other acquisition."
vest in full financial
"The shares underlying the stock units will vest in full on June 18, 2027."
FAQ
What did AGIO director Jeffrey Capello report in this Form 4 filing?
Jeffrey Capello reported equity compensation activity, including vested restricted stock units converting into common shares and new grants of stock options and RSUs. These transactions increase his equity exposure but do not involve open-market buying or selling of Agios Pharmaceuticals stock.
What stock options were granted to Jeffrey Capello by Agios Pharmaceuticals (AGIO)?
Capello received 14,950 stock options with an exercise price of $34.16 per share, expiring June 18, 2036. The filing states all underlying shares vest on June 18, 2027, aligning the option vesting with a one-year service period from the grant date.
What restricted stock units did Jeffrey Capello receive from AGIO on June 18, 2026?
He was granted 2,927 restricted stock units on June 18, 2026. Each unit represents a right to receive one common share, with all underlying shares vesting on June 18, 2027 and delivered within three business days after vesting, according to the filing footnotes.
Were there any AGIO insider stock sales or open-market purchases in this Form 4?
The Form 4 shows only equity compensation grants and derivative exercises, with no open-market purchases or sales. All transactions are coded as awards or exercises, indicating routine compensation-related activity rather than discretionary trading in Agios Pharmaceuticals shares.
When do Jeffrey Capello’s previously granted AGIO restricted stock units vest?
Restricted stock units granted on June 18, 2025 vest in full on June 18, 2026. The filing explains that shares from these units are delivered to Capello within three business days after vesting, providing a clear timetable for when he receives the underlying common stock.
AI-generated analysis. How Rhea-AI works. Not financial advice.
